<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hitt Nichols, Emma</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kröger, Nicolaus</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Reduced-Dose Conditioning Comparable to Standard Dose Prior to ASCT in MDS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">New data from the RICMAC trial showed similar rates of non-relapse mortality, incidence of relapse, and relapse-free survival in patients with myelodysplastic syndrome or secondary acute myeloid leukemia after conditioning with reduced-dose busulfan plus fludarabine vs standard-dose busulfan plus cyclophosphamide prior to allogeneic stem cell transplantation. Overall survival was higher with the reduced dose, but results were not statistically significant.</style></abstract><number><style face="normal" font="default" size="100%">55</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>